Royalty Report: Drugs, Cancer, Disease – Collection: 243433


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • DNA
  • Therapeutic
  • Drug Discovery
  • Proteins

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 243433

License Grant
For the Licensed IP Rights, the Italian Licensor grants an exclusive license under the Licensed IP Rights to conduct research and to develop, make, have made, use, offer for sale, sell and import Products in the Territory for use in the Field, and, Licensor grants a non-exclusive license under any patent, know-how or other intellectual property rights Controlled by Licensor to research and to develop, make, have made, use, offer for sale, sell and import any diagnostic product for one or more of the Exclusive Targets.
License Property
Product(s) shall mean any product that incorporates one or both of the APls and if made, used, sold, offered for sale or imported absent the license granted hereunder would infringe a Valid Claim, or that otherwise uses or incorporates the Licensor Know-How.

The patent is for Substituted Indazole Derivatives Active as Kinase Inhibitors.

RXDX-103 is an inhibitor of the cell division cycle 7-related (Cdc7) protein kinase, and RXDX-104 is a program to identify a highly selective inhibitor of the rearranged during transfection (RET) tyrosine kinase. Each of these programs is in preclinical development for the potential treatment of multiple cancers.

Loss of cell cycle control is a hallmark of cancer, and interfering with the DNA replication process is a proven strategy for cancer therapy. Currently available chemotherapies, such as anti-metabolites, topoisomerase inhibitors, and crosslinking and intercalating agents, classically take a broad-based approach to inhibiting the elongation step of DNA replication. This strategy has led to successful treatment outcomes, but off-target effects can lead to dose-limiting toxicity. Cdc7 is a serine/threonine protein kinase essential for the initiation step of DNA replication during the synthesis (S) phase.

Field of Use
The Field shall mean all fields of use, including without limitation the diagnosis, prevention or treatment of any disease, state or condition in humans or other animals.

Licensee has capabilities in the development of oncology products.

IPSCIO Record ID: 239157

License Grant
Licensor grants to the Israeli Licensee the worldwide right and exclusive license to make, have made, use, lease and sell the Licensed Products and to practice the Licensed Processes for the Field of Use to the end of the term for which the Patent Rights are granted, unless sooner terminated as provided in this Agreement.
License Property
The patents are for Short peptides which selectively modulate the activity of protein tyrosine kinases, and, Short Peptides which selectively modulate the activity of serine/threonine kinases.

KinAce platform represents one of the first practical uses of the genomics database to systematically generate drug candidates that target protein kinases. We use computer programs to analyze genomic data that then enables us to create compounds that aim to regulate kinases.  Protein kinases play a key role in the way cells communicate. When protein kinases give an inappropriate signal, the result is often a disease or other unwanted medical condition. Our KinAce platform uses a proprietary algorithm to identify unique regulatory regions within each kinase.

Field of Use
The Field of Use shall mean the diagnosis, prevention or treatment of any and all diseases or conditions in humans or animals.

IPSCIO Record ID: 369254

License Grant
Licensor grants to Licensee of the Russian Federation an exclusive right and license or  sublicense, as applicable, to the Licensed Technology to research, develop, make, have made, use, sell, offer for sale and import the Licensed Compound, Licensed Products and Licensed Product Biomarkers for the Field in the Licensee Territory.

This agreement includes a non-exclusive grant back to Licensor from Licensee.

License Property
Licensor develops, manufactures and commercializes products incorporating the proprietary compound known as tivozanib for the treatment of cancer.

Licensed Compound means the chemical compound 1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1,2-oxazol-3-yl)urea, otherwise known as tivozanib, and any and all pharmaceutically acceptable, acids, bases, esters, isomers, enantiomers, salts, stereoisomers, racemates, tautomers, polymorphs, complexes, chelates, crystalline and amorphous forms, prodrugs, solvates (including hydrates), metabolites and metabolic precursors, whether active or inactive, thereof.

Licensed patents are
Neuropilin-1 as a serum based biomarker;
Quinoline Derivatives and Quinazoline Derivatives having Azolyl Group; and,
Tivozanib Response Prediction.

Licensed Know-how is module 3 of the New Drug Application for tivozanib hydrochloride for the treatment of renal cell carcinoma.  

Licensed Product Biomarker means any and all biomarkers, including metabolite, DNA, RNA and protein profiles, discovered or developed by or on behalf of Licensor or Licensee during the Term that are for use with, including use in clinical testing of or use in any decision whether to prescribe, or relate to, are associated with or are correlated with patient populations who do or do not respond to treatment with, in the case of each, any one or more Licensed Products.

Tivozanib A potent, selective, long half-life vascular endothelial growth factor (“VEGF”) tyrosine kinase inhibitor (“TKI”) of VEGF receptors 1, 2 and 3. The Licensor is evaluating several potential paths for the development of tivozanib, including a second phase 3 trial of tivozanib in refractory renal cell carcinoma, or RCC.

Field of Use
The Field means the diagnosis, prevention and treatment of any disease or condition in humans other than non-oncologic diseases or conditions of the eye.

This agreement purpose is for the development, manufacturing and commercialization of Licensors small molecule vascular endothelial growth factor (YEGF) tyrosine kinase inhibitor tivozanib in the territories of Russia, Ukraine and the Commonwealth of Independent States (CIS), for all indications excluding ocular conditions.

IPSCIO Record ID: 245713

License Grant
The Italian Licensor grants to the UK Licensee a worldwide, exclusive license, including the right to grant sublicenses, under the Licensed Patents, to research, develop, make, have made, use, offer for sale, sell, have sold and import Licensed Products for any and all uses in the Field in the Territory.
License Property
Licensed Product means any product or service incorporating Milciclib as active ingredient for the treatment of cancer and inflammatory diseases.

Licensed Patent  8981089B2 PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS.  Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

Licensed Product means any product or service incorporating Milciclib as active ingredient for the treatment of metastatic HCC, an aggressive type of liver cancer.

Field of Use
The Licensee will have the exclusive right to develop and commercialize the Licensed Product for all diagnostic and therapeutic uses, including cancer and inflammatory diseases.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.